{"generic":"Dalbavancin","drugs":["Dalbavancin","Dalvance"],"mono":{"0":{"id":"jyc3s0","title":"Generic Names","mono":"Dalbavancin"},"1":{"id":"jyc3s1","title":"Dosing and Indications","sub":[{"id":"jyc3s1b4","title":"Adult Dosing","mono":"<b>Infection of skin AND\/OR subcutaneous tissue, Acute:<\/b> 2-dose regimen: 1000 mg IV as single dose, followed by 500 mg IV 1 week later "},{"id":"jyc3s1b5","title":"Pediatric Dosing","mono":"safety and efficacy not established in pediatric patients "},{"id":"jyc3s1b6","title":"Dose Adjustments","mono":"<ul><li><b>renal impairment, CrCl less than 30 mL\/min and not receiving hemodialysis:<\/b> 750 mg IV infusion followed by 375 mg IV infusion 1 week later<\/li><li><b>hemodialysis:<\/b> no adjustment necessary and may be administered without regard to timing of hemodialysis<\/li><li><b>hepatic impairment, mild (Child-Pugh class A):<\/b> no adjustment necessary<\/li><li><b>hepatic impairment, moderate to severe (Child-Pugh class B or C):<\/b> use with caution.<\/li><\/ul>"},{"id":"jyc3s1b7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><br\/>Infection of skin AND\/OR subcutaneous tissue, Acute<br\/><b>Non-FDA Labeled Indications<\/b><br\/>Bacteremia, Catheter-related<br\/>"}]},"3":{"id":"jyc3s3","title":"Contraindications\/Warnings","sub":[{"id":"jyc3s3b9","title":"Contraindications","mono":"hypersensitivity to dalbavancin <br\/>"},{"id":"jyc3s3b10","title":"Precautions","mono":"<ul><li>Gastrointestinal:<\/li><li>-- patients who experience diarrhea following dalbavancin use, including occurrence more than 2 months after administration, should be evaluated for clostridium difficile-associated diarrhea (CDAD) and appropriate treatment (eg, discontinuation of dalbavancin use, antibiotic treatment of C difficile, surgical evaluation, fluid and electrolyte management, protein supplementation) should be implemented if suspected or confirmed<\/li><li>Hepatic:<\/li><li>-- ALT elevation greater than 3 times ULN has been reported<\/li><li>Immunologic:<\/li><li>-- serious hypersensitivity (anaphylactic) and skin reactions have been reported; discontinue use if an allergic reaction occurs<\/li><li>-- give cautiously to patients with a history of hypersensitivity to glycopeptides because of possible cross-sensitivity<\/li><li>Other:<\/li><li>-- infusion-related reactions, including flushing of the upper body, urticaria, pruritus, or rash, may occur; administer in a dilute solution over at least 30 minutes and stopping or slowing the infusion time may lessen the reactions<\/li><\/ul>"},{"id":"jyc3s3b11","title":"Pregnancy Category","mono":"C (FDA)<br\/>"},{"id":"jyc3s3b12","title":"Breast Feeding","mono":"Micromedex: Infant risk cannot be ruled out.<br\/>"}]},"5":{"id":"jyc3s5","title":"Adverse Effects","mono":"<b>Common<\/b><ul><li><b>Gastrointestinal:<\/b>Constipation (18.2%), Diarrhea (4.4%), Nausea (5.5%)<\/li><li><b>Neurologic:<\/b>Headache (4.7%)<\/li><\/ul><b>Serious<\/b><ul><li><b>Gastrointestinal:<\/b>Clostridium difficile colitis (Less than 2%), Gastrointestinal hemorrhage (Less than 2%)<\/li><li><b>Hepatic:<\/b>Alkaline phosphatase raised (Less than 2%), ALT\/SGPT level raised (0.8%), Aminotransferase abnormal, Increased (Less than 2%), Hepatotoxicity (Less than 2%)<\/li><li><b>Other:<\/b>Infusion reaction (Less than 2%)<\/li><\/ul>"},"6":{"id":"jyc3s6","title":"Drug Name Info","sub":{"0":{"id":"jyc3s6b17","title":"US Trade Names","mono":"Dalvance<br\/>"},"2":{"id":"jyc3s6b19","title":"Class","mono":"<ul><li>Antibacterial<\/li><li>Glycopeptide<\/li><\/ul>"},"3":{"id":"jyc3s6b20","title":"Regulatory Status","mono":"RX<br\/>"},"4":{"id":"jyc3s6b21","title":"Generic Availability","mono":"No<br\/>"}}},"7":{"id":"jyc3s7","title":"Mechanism Of Action","mono":"Dalbavancin is a semisynthetic lipoglycopeptide antibacterial agent inhibits cell wall peptidoglycan cross-linking by binding to the terminal of the D-alanyl-D-alaine pentapeptide chain in nascent peptidoglycan. Even though the mechanism of action is similar between dalbavancin and vancomycin, some vancomycin-resistant enterocci and staphylococci with intermediate sensitivity to glycopeptides remain sensitive to dalbavancin.<br\/>"},"8":{"id":"jyc3s8","title":"Pharmacokinetics","sub":[{"id":"jyc3s8b23","title":"Absorption","mono":"Tmax, IV: 0.5 to 1 hour.<br\/>"},{"id":"jyc3s8b24","title":"Distribution","mono":"Vd: adults, 9.75 to 15.7 L <br\/>"},{"id":"jyc3s8b25","title":"Metabolism","mono":"Not affected by cytochrome P450 substrates, inhibitors, inducers or selected concomitant medications <br\/>"},{"id":"jyc3s8b26","title":"Excretion","mono":"<ul><li>Fecal: 20% unchanged<\/li><li>Renal: 33% unchanged<\/li><li>Dialyzable: Yes, less than 6%<\/li><li>Total body clearance: 0.0473 L\/hr<\/li><\/ul>"},{"id":"jyc3s8b27","title":"Elimination Half Life","mono":"8.5 days <br\/>"}]},"9":{"id":"jyc3s9","title":"Administration","mono":"<b>Intravenous<\/b><br\/><ul><li>reconstitute with sterile water for injection; to avoid foaming, swirl to dissolve; do not shake<\/li><li>dilute in D5W to a final concentration of 1 to 5 mg\/mL; total time from reconstitution to administration should not exceed 48 hours<\/li><li>administer over 30 minutes; rapid administration may cause flushing, urticaria, pruritus, or rash; stopping or slowing the infusion will lessen these reactions<\/li><li>flush IV line before and after infusion with D5W; do not use NS, precipitation may occur<\/li><li>do not infuse concomitantly with other medications or electrolytes<\/li><\/ul>"},"10":{"id":"jyc3s10","title":"Monitoring","mono":"<ul><li>improvement in acute bacterial skin and skin structure infections is indicative of efficacy<\/li><li>diarrhea; may indicate overgrowth of Clostridium difficile; may occur at late as 2 months following therapy discontinuation<\/li><li>hypersensitivity reactions including anaphylaxis; increased risk in patients with a history of glycopeptide allergy<\/li><\/ul>"},"11":{"id":"jyc3s11","title":"How Supplied","mono":"<b>Dalvance<\/b><br\/>Intravenous Powder for Solution: 500 MG<br\/>"},"13":{"id":"jyc3s13","title":"Clinical Teaching","mono":"<ul><li>Warn patient that serious allergic reactions may occur and require immediate medical attention.<\/li><li>Side effects may include nausea, vomiting, diarrhea, headache, rash, or itching.<\/li><li>Instruct patient to report severe watery or bloody diarrhea.<\/li><li>Advise patient of the importance for completing the entire course of therapy.<\/li><\/ul>"}}}